Form
SCHEDULE 13D/A
Active or control-oriented beneficial ownership filing.
ORBIMED ADVISORS LLC - 06 Oct 2026 SCHEDULE 13D/A Report for ArriVent BioPharma, Inc. Common Stock (AVBP)
- Filing manager
- ORBIMED ADVISORS LLC
- Reporting owner
- ORBIMED ADVISORS LLC
- Beneficially owned shares
- 2,875,962 shares
- Large-stake signal
-
Ownership
5.8%Beneficial ownership of this reported class.
Shares
2,875,962 sharesShares beneficially owned as disclosed.
Event date
06 Oct 2026Date tied to the ownership event or amendment.
Accepted by SEC
08 Oct 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 5.8%
- Symbol
- AVBP
- Shares outstanding
- 49,585,552 shares
- SEC form
- SCHEDULE 13D/A
- Accepted by SEC
- 08 Oct 2026, 18:39:36 UTC
- Event date
- 06 Oct 2026
- Prior SEC filing
- 13 Aug 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
5 source fields
Key filing fact
ORBIMED ADVISORS LLC disclosed 5.8% ownership in ArriVent BioPharma, Inc. Common Stock (AVBP) on 06 Oct 2026.
Key facts
- ORBIMED ADVISORS LLC filed SCHEDULE 13D/A for ArriVent BioPharma, Inc. Common Stock (AVBP).
- Disclosed ownership: 5.8%.
- Date of event: 06 Oct 2026.
Change
- Previous schedule filing date: 13 Aug 2025.
- Current filing was accepted on 08 Oct 2026, 18:39.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (4)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 5.8% | 2,875,962 | 0 | 2,875,962 | /s/ Carl L. Gordon | Member | 0001055951 |
| OrbiMed Capital GP VIII LLC | 2.9% | 1,437,981 | 0 | 1,437,981 | /s/ Carl L. Gordon | Member of OrbiMed Advisors LLC | 0001845804 |
| OrbiMed Asia GP IV, L.P. | 2.9% | 1,437,981 | 0 | 1,437,981 | /s/ Carl L. Gordon | Director of OrbiMed Advisors IV Limited | 0001966836 |
| OrbiMed Advisors IV Limited | 2.9% | 1,437,981 | 1,437,981 | 0 | /s/ Carl L. Gordon | Director | 0001966835 |
CIK / CUSIP context first